Description
Coming soon.
CBL-514, supplied in lyophilized powdered vials for research use applications.
CBL-514 is designed to selectively induce adipocyte apoptosis to precisely reduce subcutaneous fat at the injection site without causing necrosis or damage to surrounding tissue. CBL-514 has demonstrated broad therapeutic potential across multiple indications, including non-surgical subcutaneous fat reduction and moderate-to-severe cellulite.
Clinical Research & Findings
- Abdominal Fat: In Phase 2 trials, single or repeated local injections significantly reduced targeted abdominal subcutaneous fat volume and thickness. [1, 2]
- Visceral Fat: Data presented at the 2026 European Association for the Study of Diabetes meeting showed an average 12% reduction in visceral fat in treated human participants after a 12-week course.[1, 2]
- Safety Profile: Generally well tolerated; reported side effects are mostly mild-to-moderate, temporary injection-site reactions like pain, swelling, bruising, and redness. [1, 2, 3]
- Approval Status: Not yet FDA-approved as of late 2026, though Phase 3 global pivotal trials (SUPREME-01) are actively recruiting and underway. [1, 2, 3]
https://aminoshoppe.com/lab-tests/